Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Trial Parameters
Brief Summary
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Eligibility Criteria
Inclusion criteria: 1. Eligible are myeloma patients after standard first-line induction treatment. Additional induction regimens in refractory myeloma patients are allowed. 2. Patients must be considered fit for subsequent consolidation with high-dose chemotherapy with autologous stem cell transplantation. 3. Patients must be aged 18-75 years. 4. Patients must have an ECOG \<3. 5. Patients must have a creatinine clearance ≥35 ml/min. 6. Patients must have an LVEF ≥40% within three months prior to start of study HDCT. 7. Patients must have given voluntary written informed consent. Exclusion criteria: 1. Patients with an uncontrolled acute infection. 2. Patients with a transplantation comorbidity index (HCTCI) \> 6 points. 3. Patients with concurrent active malignant disease with the exception of basalioma/spinalioma of the skin or early-stage cervix carcinoma, or early-stage prostate cancer. Previous treatment for other malignancies (not listed above) must have been terminated at least